[Heparin use in geriatrics and risk profiles of treated patients. A survey in France].
OBJECTIVE
Nursing home residents and geriatric ward patients have a high risk of venous thromboembolism. Prevention is a major challenge. We conducted a one-day audit to ascertain heparin use patterns in a large sample of geriatric facilities in France.


METHODS
This one-day audit was made with a questionnaire mailed to 150 geriatric centers in France. Items were the number of subjects receiving heparin on the day of the survey, and for each of these subjects, the reason for the prescription, risk factors for venous thromboembolism and date of treatment onset.


RESULTS
Ninety-six centers (63%) participated. These centers had 14,208 beds the day of the survey (short-term hospitalization, day-care hospitalization, nursing homes, retirement homes). These centers reported 1,312 subjects (9.2%) receiving heparin on the day of the survey. Their mean age was 83.4 days. Among the hospital centers, heparin had been prescribed in 33.4% of the short-term hospitalization patients, 27.3% of the day-care patients, and 5.6% of the nursing home patients. Heparin was prescribed for prophylaxis in 1,143 patients (87%)--basically low-molecular-weight heparin. These patients had on the average 3.33 risk factors. The duration of preventive treatment was more than 30 days in 481 subjects (50%) and 161 (17%) had received heparin for 6 months or more.


CONCLUSIONS
Prevention of venous thromboembolism is a major concern in geriatric centers in France. Although the preventive efficacy has not been clearly demonstrated in geriatric medical patients, low-molecular weight heparin is widely used for this purpose with, in a large number of cases, very long treatment durations.
Service de Médecine interne gériatrique, Hôpital René Muret et Université Paris Nord, F 93270 Sevran.
J
J
Belmin
S
S
Medjahed
C
C
Trivalle
P
P
Lutzler
D000368:Aged; D000369:Aged, 80 and over; D003625:Data Collection; D004363:Drug Utilization; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005602:France; D005853:Geriatrics; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012307:Risk Factors
D005343:Fibrinolytic Agents; D006493:Heparin